189
X. G. SUN ET AL.
into the clinical care of the patients [17]. Provided that
large-scale data sets from genomics, proteomics, popula-
tion genetics, and imaging drives research at an un-
precedented pace, translational Chinese medicine is to
integrate these data with the safety and efficacy of TCM
to take deeper insights into syndrome differentiation and
formulae [18]. The gene studies pertaining to pharmaco-
genetical variations in response to Chinese medicine re-
sponse, optimum dose for adequate response, patho-
physiology changes of a particular formula, patient
population predisposition to adverse effects would pro-
vide the pharmacogenetic basis of drug effect variations
in patients. In the long run, the application of pharmaco-
genetics in Chinese medicine will significantly contrib-
ute to the individualization of drug therapy, known as
personalized Chinese medicine.
As the science matures, the empiricism of medical
practice is replaced by mechanism-based targeted dia-
gnostics and therapeutics. Molecular sciences, including
the evolving science of biomarkers, have catalyzed the
development of diagnostic and therapeu tic platforms tail-
ored to the individual patient profiles, paving the way for
the deployment of personalized Chinese medicine. There-
fore, it is time to advance the concept of translational
Chinese medicine to make Chinese medicine a personal-
ized and balanced medicine, with sound safety, good ef-
ficacy and strict quality control.
6. Acknowledgements
This Project was supported by grants from the National
Natural Sciences Foundation of China (No. 81173168,
30973699).
7. References
[1] S. P. Mankoff, C. Brander, S. Ferrone and F. M. Marin-
cola, “Lost in Translation: Obstacles to Translational
Medicine,” Journal of Translational Medicine, Vol. 2, No.
1, 2004, pp. 14-18.
[2] X. G. Sun, Q. Liu, Y. Y. Zhao and Y. Cai, “Confirmation,
Falsification, or Hermeneutics?” Journal of Nanjing
University of Traditional Chinese Medicine (Social Sci-
ence Edition), Vol. 8, No. 1, 2007, pp. 30-33.
[3] J. Xu and Y. Yang, “Traditional Chinese Medicine in the
Chinese Health Care System,” Health Policy, Vol. 90, No.
2-3, 2009, pp. 133-139.
dx.doi.org/10.1016/j.healthpol.2008.09.003
[4] B. Wu, M. Liu, H. Liu, W. Li, S. Tan, S. Zhang, et al.,
“Meta-Analysis of Traditional Chinese Patent Medicine
for Ischemic Stroke,” Stroke, Vol. 38, No. 6, 2007, pp.
1973-1979.
[5] X. G. Sun, “The Negative Influences of Pragmatism on
Traditional Chinese Medicine (TCM),” Medicine and
Philosophy, Vol. 19, No. 9, 1998, pp. 19-21.
[6] B. Liu, Y. Zhang, J. Hu, L. He and X. Zhou, “Thinking
and Practice of Accelerating Transformation of Tradi-
tional Chinese Medicine from Experience Medicine to
Evidence-Based Medicine,” Frontier Medical, Vol. 5, No.
2, 2011, pp. 163-170.
dx.doi.org/10.1007/s11684-011-0143-9
[7] R. L. Hauger, V. Risbrough, R. H. Oakley, J. A. Oli-
vares-Reyes and F. M. Dautzenberg, “Role of CRF Re-
ceptor Signaling in Stress Vulnerability, Anxiety, and
Depression,” Annals of the New York Academy of Sci-
ences, Vol. 1179, No. 2009, pp. 120-143.
[8] M. W. Saif, F. Lansigan, S. Ruta, L. Lamb, M. Mezes, K.
Elligers, et al., “Phase I Study of the Botanical Formu-
lation PHY906 with Capecitabine in Advanced Pancre-
atic and Other Gastrointestinal Malignancies,” Phyto-
medicine, Vol. 17, No. 3-4, 2010, pp. 161-169.
[9] Y. Yen, S. So, M. Rose, M. W. Saif, E. Chu, S. H. Liu, et
al., “Phase I/II Study of PHY906/Capecitabine in Ad-
vanced Hepatocellular Carcinoma,” Anticancer Research,
Vol. 29, No. 10, 2009, pp. 4083-4092.
[10] X. Huang, F. Qin, H. M. Zhang, H. B. Xiao, L. X. Wang,
X. Y. Zhang, et al., “Cardioprotection by Guanxin II in
Rats with Acute Myocardial Infarction Is Related to Its
Three Compounds,” Journal of Ethnopharmacology, Vol.
121, No. 2, 2009, pp. 268-273.
dx.doi.org/10.1016/j.jep.2008.10.029
[11] R. Tilton, A. A. Paiva, J. Q. Guan, R. Marathe, Z. Jiang,
W. van Eyndhoven, et al., “A Comprehensive Platform
for Quality Control of Botanical Drugs (Phytomicsqc): A
Case Study of Huangqin Tang (HQT) and PHY906,”
Chinese Medicine, Vol. 5, 2010, pp. 1-15.
dx.doi.org/10.1186/1749-8546-5-30
[12] Y. Sun, Y. Dong, H. J. Jiang, T. T. Cai, L. Chen, X. Zhou,
et al., “Dissection of the Role of Paeoniflorin in the Tra-
ditional Chinese Medicinal Formula Si-Ni-San against
Contact Dermatitis in Mice,” Life Sciences, Vol. 84, No.
11-12, 2009, pp. 337-344.
dx.doi.org/10.1016/j.lfs.2008.12.023
[13] Y. Wang, X. Huang, F. Qin, P. Ren, Z. Zhu, R. Fan, et al.,
“A Strategy for Detecting Optimal Ratio of Cardioprotec-
tion-Dependent Three Compounds as Quality Control of
Guan-Xin-Er-Hao Formula,” Journal of Ethnopharma-
cology, Vol. 133, No. 2, 2011, pp. 735-742.
dx.doi.org/10.1016/j.jep.2010.11.006
[14] Y. Li, T. Wu, H. Shang and K. Yang, “Strategies for
Promoting the Development of Evidence-Based Medicine
in China,” Journal of Evidence-Based Medicine, Vol. 2,
No. 1, 2009, pp. 47-52.
dx.doi.org/10.1111/j.1756-5391.2009.01012.x
[15] M. U. Naidu, “Promise of Translational Medicine: An
Evidence-Based Therapeutics,” Indian Journal of Phar-
macology, Vol. 43, No. 2, 2011, pp. 103-104.
dx.doi.org/10.4103/0253-7613.77332
[16] G. K. Merijohn and M. G. Newman, “The Translational
Clinical Practice System: A Way to Implement the Evi-
dence-Based Approach in the Dental Office,” Journal of
Copyright © 2011 SciRes. CM